The Relative Effects of Single Doses of Olmesartan Medoxomil, Irbesartan and Valsartan at High Dosage Levels on the Renin-Angiotensin-Aldosterone System in Healthy Normal Subjects

Daiichi Sankyo0 个研究点目标入组 20 人开始时间: 2004年11月最近更新: 2005年9月16日

适应症

试验速览

阶段: 4 期
状态: 已完成
发起方: Daiichi Sankyo
入组人数: 20
主要终点: To characterize the plasma renin activity (PRA) and urinary aldosterone response patterns to single doses of olmesartan medoxomil, irbesartan, and valsartan compared to placebo in normal volunteers.

研究概览研究设计入排标准结局指标研究者记录与标识符相似试验

研究概览

简要总结

To assess the effects of 3 blood pressure drugs, called angiotensin receptor blockers, on the blood pressure control systems in healthy subjects.

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Crossover
主要目的: Treatment
盲法: Single

入排标准

年龄范围: 18 Years 至 65 Years（Adult, Older Adult）
性别: All
接受健康志愿者: 是

入选标准

•Men and women between the ages of 18 to 65
•In good health

排除标准

•Any serious health problems
•Positive test for HIV, Hepatitis B and C
•History of drug and alcohol abuse

结局指标

主要结局

To characterize the plasma renin activity (PRA) and urinary aldosterone response patterns to single doses of olmesartan medoxomil, irbesartan, and valsartan compared to placebo in normal volunteers.

次要结局

未报告次要终点

研究者

发起方

Daiichi Sankyo

申办方类型

Industry

相似试验

已完成

4 期

Treatment of High Blood Pressure Using Olmesartan With Hydrochlorothiazide Compared to an ACE Inhibitor With a Calcium Channel BlockerHypertension

NCT00185120Daiichi Sankyo152

已完成

3 期

Parallel-Group Comparison of Olmesartan (OLM), Amlodipine (AML) and Hydrochlorothiazid (HCTZ) in HypertensionEssential Hypertension

NCT00923091Daiichi Sankyo2,689

已完成

4 期

New Angiotensin II Receptor Blocker Azilsartan Study for Stronger Blood Pressure LoweringHypertension

NCT01609959Nara Medical University70

已完成

3 期

Combination of Olmesartan and Hydrochlorothiazide in Essential HypertensionEssential Hypertension

NCT00430950Daiichi Sankyo1,011

已完成

4 期

A Comparison of the Effect of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on the Ability of Overweight Patients With High Blood Pressure to Respond to InsulinMetabolic SyndromeHypertensionInsulin Resistance

NCT00185094Daiichi Sankyo60